Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes

Journal of Experimental Medicine

Volumn 185, Issue 5, 1997, Pages 833-841

  Theobald, Matthias ^a,b   Biggs, Judith ^a   Hernández, Javier ^a   Lustgarten, Joseph ^a   Labadie, Colleen ^a   Sherman, Linda A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SUPPRESSOR GENE;

ANIMALS; ANTIGEN PRESENTATION; H-2 ANTIGENS; HUMANS; IMMUNE TOLERANCE; MICE; MICE, MUTANT STRAINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030892137     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.5.833     Document Type: Article

References (63)

1. Levine, A.J., J. Momand, and C.A. Finlay. 1991. The p53 tumor suppressor gene. Nature (Lond.). 351:453-456.
2. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science (Wash. DC). 253:49-53.
3. Rogel, A., M. Popliker, C.G. Webb, and M. Oren. 1985. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol. 5: 2851-2855.
4. Milner, J. 1984. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature (Lond.). 310:143-145.
5. Terada, N., J.J. Lucas, and E.W. Gelfand. 1991. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J. Immunol. 147:698-704.
6. Kappler, J.W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell. 49:273-280.
7. Mac-Donald, H.R., R. Schneider, R.K. Lees, R.G. Howe, H. Acha-Orbea, H. Festenstein, R.M. Zinkernagel, and H. Hengartner. 1988. T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (Lond.). 332:40-45.
8. + thymocytes. Nature (Lond.). 333:742-746.
9. + T cells. Immunol. Rev. 117:213-234.
10. Allen, P.M. 1994. Peptides in positive and negative selection: a delicate balance. Cell. 76:593-596.
11. Ashton-Rickardt, P.G., A. Bandeira, J.R. Delaney, L. Van Kaer, H.P. Pircher, R.M. Zinkernagel, and S. Tonegawa. 1994. Evidence for a differential avidity model of T cell selection in the thymus. Cell. 76:651-663.
12. Miller, J.F.A.P., G. Morahan, J. Allison, and M. Hoffmann. 1991. A transgenic approach to the study of peripheral T-cell tolerance. Immunol. Rev. 122:103-116.
13. Hmmerling, G.J., G. Schnrich, I. Ferber, and B. Arnold. 1993. Peripheral tolerance as a multi-step mechanism. Immunol. Rev. 133:93-104.
14. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
15. + T cells. Proc. Natl. Acad. Sci. USA. 91:3171-3175.
16. Noguchi, Y., E.G. Richards, Y.-T. Chen, and L.J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA. 92:2219-2223.
17. Mayordomo, J.I., D.J. Loftus, H. Sakamoto, C.M. De Cesare, P.M. Appasamy, M.T. Lotze, W.J. Storkus, E. Appella, and A.B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357-1365.
18. Roth, J., D. Dittmer, D. Rea, J. Tartaglia, E. Paoletti, and A.J. Levine. 1996. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc. Natl. Acad. Sci. USA. 93: 4781-4786.
19. Houbiers, J.G.A., H.W. Nijman, S.H. van der Burg, J.W. Drijfhout, P. Kenemans, C.J. van tie Velde, A. Brand, F. Momburg, W.M. Kast, and C.J.M. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072-2077.
20. Nijman, H.W., J.G.A. Houbiers, S.H. van der Burg, M.P.M. Vierboom, P. Kenemans, W.M. Kast, and C.J.M. Melief. 1993. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother. 14:121-126.
21. Nijman, H.W., S.H. van den Burg, M.P.M. Vierboom, J.G.A. Houbiers, W.M. Kast, and C.J.M. Melief. 1994. p53, a potential target for tumor-directed T cells. Immunol. Lett. 40:171-178.
22. Tilkin, A.-F., R. Lubin, T. Soussi, V. Lazar, N. Janin, M.-C. Mathieu, I. Lefrere, C. Carlu, M. Roy, M. Kayibanda et al. 1995. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 25: 1765-1169.
23. Theobald, M., J. Biggs, D. Dittmer, A.J. Levine, and L.A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA. 1995, 92:11993-11997.
24. Harlow, E., N.M. Williamson, R. Ralston, D.M. Helfman, and T.E. Adams. 1985. Molecular Cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol. Cell. Biol. 5:1601-1610.
25. Sherman, L.A., S.V. Hesse, M.J. Irwin, D. La Face, and P. Peterson. 1992. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science (Wash. DC). 258:815-818.
26. Lowe, S.W., E.M. Schmitt, S.W. Smith, B.A. Osborne, and T. Jacks. 1993. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature (Lond.). 362:847-849.
27. Irwin, M.J., W.R. Heath, and L.A. Sherman. 1989. Species- restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogeneic response. J. Exp. Med. 170:1091-1101.
28. Vitiello, A., D. Marchesini, J. Furze, L.A. Sherman, and R.W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007-1015.
29. Samberg, N.L., H.C. Scarlett, and H.J. Stauss. 1989. The α3 domain of major histocompatibility complex class I molecules play a critical role in cytotoxic T lymphocyte stimulation. Eur. J. Immunol. 19:2349-2354.
30. Kalinke, U., B. Arnold, and G.J. Hmmerling. 1990. Strong xenogeneic HLA response in transgenic mice after introducing an α3 domain into HLA B27. Nature (Lond.). 348:642-644.
31. Engelhard, V.H., E. Lacy, and J.P. Ridge. 1991. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J. Immunol. 146:1226-1232.
32. LaFace, D.M., M. Vestberg, Y. Yang, R. Srivastava, J. DiSanto, N. Flomenberg, S. Brown, L.A. Sherman, and P.A. Peterson. 1995. Human CD8 transgene regulation of HLA recognition by murine T cells. J. Exp. Med. 182:1315-1325.
33. Sun, J., D.J. Leahy, and P.B. Kavathas. 1995. Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the α2 and α3 domains of MHC class I. J. Exp. Med. 182:1275- 1280.
34. + influenza matrix peptide in human MHC class I transgenic mice. J. Immunol. 153:4458-4467.
35. Lehner, P.J., E.C.Y. Wang, P.A.H. Moss, S. Williams, K. Platt, S.M. Friedman, J.I. Bell, and L.K. Borysiewicz. 1995. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J. Exp. Med. 181:79-91.
36. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W.M. Kast, C.J.M. Melief, C. Oseroff, L. Yuan, J. Ruppert et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586-5592.
37. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V.H. Engelhard, S.M. Feinstone, and J.A. Berzofsky. 1995. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154:2733-2742.
38. Wentworth, P.A., A. Vitiello, J. Sidney, E. Keogh, R.W. Chesnut, H. Grey, and A. Sette. 1996. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26:97-101.
39. Clarke, A.R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.). 362:849-852.
40. Benveniste, P., and A. Cohen. 1995. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA. 92:8373-8377.
41. Boehme, S.A., and M.J. Lenardo. 1996. TCR-mediated death of mature T lymphocytes occurs in the absence of p53. J. Immunol. 156:4075-4078.
42. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A.K. Teresky, M. Moore, C. Finlay, and A.J. Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42-46.
43. Masuda, H., C. Miller, H.P. Koeffler, H. Battifora, and M.J. Cline. 1987. Rearrangements of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA. 84:7716-7719.
44. Hinds, P.W., C.A. Finlay, R.S. Quartin, S.J. Baker, E.R. Fearon, B. Vogelstein, and A.J. Levine. 1990. Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1: 571-580.
45. Harvey, D. M., and A. J. Levine. 1991. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5:2375- 2385.
46. Vitiello, A., and L.A. Sherman. 1983. Recognition of influenza-infected cells by cytolytic T lymphocyte clones: Determinant selection by class I restriction elements. J. Immunol. 131:1635-1640.
47. Parham, P., and W.F. Bodmer. 1978. Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature (Lond.). 276:397-398.
48. O'Neil, B.H., Y. Kawakami, N.P. Restifio, J.R. Bennink, J.W. Yewdell, and S.A. Rosenberg. 1993. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol. 151:1410-1418.
49. Earl, P. L., A.W. Hugin, and B. Moss. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus J. Virol. 64:2448-2451.
50. Schild, H., O. Rtzschke, H. Kalbacher, and H.G. Rammensee. 1990. Limit of T cell tolerance to self proteins by peptide presentation. Science (Wash. DC). 247:1587-1589.
51. Nistico, P., R. Tecce, P. Giacomini, A. Cavallari, I. D'Agnano, P.B. Fisher, and P.G. Natali. 1990. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res. 50:7422-7429.
52. Mortarini, R., F. Belli, G. Parmiani, and A. Anichini. 1990. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-β, rTNF-α, rIFN-γ, rIL4 and their combinations. Int. J. Cancer. 45:334-341.
53. d-restricted cytotoxic T lymphocytes. J. Exp. Med. 173: 849-858.
54. Heath, W.R., J. Allison, M.W. Hoffmann, G. Schnrich, G.J. Hmmerling, B. Arnold, and J.F.A.P. Miller. 1992. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature (Lond.). 359:547-549.
55. von Herrath, M.G., J. Dockter, and M.B.A. Oldstone. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity. 1:231-242.
56. von Herrath, M.G., J. Dockter, M. Nerenberg, J.E. Gairin, and M.B.A. Oldstone. 1994. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. 180: 1901-1910.
57. Liu, G.Y., P.J. Fairchild, R.M. Smith, J.R. Prowie, D. Kioussis, and D.C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 3:407-415.
58. Schaeffer, E.B., A. Sette, D.L. Johnson, M.C. Bekoff, J.A. Smith, H.M. Grey, and S. Buus. 1989. Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc. Natl. Acad. Sci. USA. 86: 4649-4653.
59. Hogquist, K.A., S.C. Jameson, W.R. Heath, J.L. Howard, M.J. Bevan, and F.R. Carbone. 1994. T-cell receptor antagonist peptides induce positive selection. Cell. 76:17-27.
60. + T cells. Immunity. 3:79-86.
61. Pircher, H., U.H. Rohrer, D. Moskophidis, R.M. Zinkernagel, and H. Hengartner. 1991. Lower receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature (Lond.). 351:482-485.
62. Karjalainen, K. 1994. High sensitivity, low affinity-paradox of T-cell receptor recognition. Curr. Opin. Immunol. 6:9-12.
63. Speiser, D.E., D. Kyburz, U. Stuebi, H. Hengartner, and R.M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149:972-980.